ATB Capital Has Lowered Expectations for Organigram (TSE:OGI) Stock Price

Organigram (TSE:OGI) had its price objective decreased by stock analysts at ATB Capital from C$5.25 to C$3.50 in a note issued to investors on Tuesday,BayStreet.CA reports. ATB Capital’s price objective indicates a potential upside of 66.67% from the stock’s current price.

Separately, Canaccord Genuity Group dropped their price target on shares of Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating on the stock in a research report on Monday, December 9th.

Organigram Trading Down 7.9 %

TSE:OGI opened at C$2.10 on Tuesday. Organigram has a 1 year low of C$1.61 and a 1 year high of C$3.95. The business has a fifty day moving average of C$2.26 and a 200-day moving average of C$2.30. The company has a debt-to-equity ratio of 1.13, a quick ratio of 2.62 and a current ratio of 6.95. The stock has a market cap of C$228.00 million, a price-to-earnings ratio of -0.84, a PEG ratio of 0.42 and a beta of 1.13.

Insider Activity at Organigram

In other news, Senior Officer Paolo De Luca sold 12,014 shares of the firm’s stock in a transaction on Thursday, October 24th. The stock was sold at an average price of C$2.52, for a total transaction of C$30,275.28. Company insiders own 31.32% of the company’s stock.

Organigram Company Profile

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED’ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.